On 17 June 2021 the Financial Times published an Opinion on the IP Waiver for Covid-19 vaccines, co-authored by Professor Duncan Matthews, Director of the Queen Mary Intellectual Property Research Institute, and Professor Timo Minssen, Director of the Centre for Advanced Studies in Biomedical Innovation Law, University of Copenhagen. They argue that "the Covid response requires a toolkit of policies to ensure adequate vaccine manufacturing and delivery. The significance of IP and its interface with collaboration and knowledge transfer in responding to these challenges must be key components of that approach... A focus on the role of IP should trigger greater transparency and further studies, more nuanced debates and innovative approaches for tackling future challenges.”